Press release
Atopic Dermatitis Pipeline Review 2024: Clinical Trials Update and Market Impact by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan PLC, Bausch Health
The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Atopic Dermatitis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atopic Dermatitis Market.
Some of the key takeaways from the Atopic Dermatitis Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Atopic Dermatitis treatment therapies with a considerable amount of success over the years.
*
Atopic Dermatitis companies working in the treatment market are Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others, are developing therapies for the Atopic Dermatitis treatment
*
Emerging Atopic Dermatitis therapies in the different phases of clinical trials are- PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, and others are expected to have a significant impact on the Atopic Dermatitis market in the coming years.
*
In March 2024, Sanofi has reported promising results from the second phase of a study involving the OX40 antibody amlitelimab, demonstrating sustained improvement in treating moderate to severe atopic dermatitis symptoms in patients who had previously received treatment.
Atopic Dermatitis Overview
Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by red, itchy rashes. It is a type of dermatitis that tends to flare up periodically and often occurs in individuals with a personal or family history of allergic conditions like asthma, hay fever, or allergic rhinitis.
Get a Free Sample PDF Report to know more about Atopic Dermatitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight [https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Atopic Dermatitis Drugs Under Different Phases of Clinical Development Include:
*
PF 07242813: Pfizer
*
KT-474: Kymera Therapeutics
*
BEN2293: BenevolentAI
*
MEDI3506: AstraZeneca
*
Q301: Qurient
*
SB011: Sterna Biologicals
*
Tradipitant: Vanda Pharmaceuticals
*
Roflumilast: Arcutis Biotherapeutics
Atopic Dermatitis Route of Administration
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Atopic Dermatitis Molecule Type
Atopic Dermatitis Products have been categorized under various Molecule types, such as
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Atopic Dermatitis Pipeline Therapeutics Assessment
*
Atopic Dermatitis Assessment by Product Type
*
Atopic Dermatitis By Stage and Product Type
*
Atopic Dermatitis Assessment by Route of Administration
*
Atopic Dermatitis By Stage and Route of Administration
*
Atopic Dermatitis Assessment by Molecule Type
*
Atopic Dermatitis by Stage and Molecule Type
DelveInsight's Atopic Dermatitis Report covers around 110+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Atopic Dermatitis product details are provided in the report. Download the Atopic Dermatitis pipeline report to learn more about the emerging Atopic Dermatitis therapies [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Atopic Dermatitis Therapeutics Market include:
Key companies developing therapies for Atopic Dermatitis are - GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regenron Pharmaceutical Inc., Abbvie Inc., Allergan PLC, Bausch Health Companies Inc., Evelo Biosciences, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma, and others.
Atopic Dermatitis Pipeline Analysis:
The Atopic Dermatitis pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
*
Atopic Dermatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Atopic Dermatitis drugs and therapies [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Atopic Dermatitis Pipeline Market Drivers
*
Rising prevalence of AD, escalating expenditure on health care, potential Emerging Therapies are some of the important factors that are fueling the Atopic Dermatitis Market.
Atopic Dermatitis Pipeline Market Barriers
*
However, over-the-counter medications, outdated treatment recommendations - Poor prognosis and treatment adherence and other factors are creating obstacles in the Atopic Dermatitis Market growth.
Scope of Atopic Dermatitis Pipeline Drug Insight
*
Coverage: Global
*
Key Atopic Dermatitis Companies: Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others
*
Key Atopic Dermatitis Therapies: PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, and others
*
Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
*
Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers
Request for Sample PDF Report for Atopic Dermatitis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Atopic Dermatitis Report Introduction
2. Atopic Dermatitis Executive Summary
3. Atopic Dermatitis Overview
4. Atopic Dermatitis- Analytical Perspective In-depth Commercial Assessment
5. Atopic Dermatitis Pipeline Therapeutics
6. Atopic Dermatitis Late Stage Products (Phase II/III)
7. Atopic Dermatitis Mid Stage Products (Phase II)
8. Atopic Dermatitis Early Stage Products (Phase I)
9. Atopic Dermatitis Preclinical Stage Products
10. Atopic Dermatitis Therapeutics Assessment
11. Atopic Dermatitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Atopic Dermatitis Key Companies
14. Atopic Dermatitis Key Products
15. Atopic Dermatitis Unmet Needs
16 . Atopic Dermatitis Market Drivers and Barriers
17. Atopic Dermatitis Future Perspectives and Conclusion
18. Atopic Dermatitis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atopic-dermatitis-pipeline-review-2024-clinical-trials-update-and-market-impact-by-delveinsight-glaxosmithkline-plc-nestle-sa-pfizer-inc-regeneron-pharma-abbvie-allergan-plc-bausch-health]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Pipeline Review 2024: Clinical Trials Update and Market Impact by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan PLC, Bausch Health here
News-ID: 3806459 • Views: …
More Releases from ABNewswire
Manhattan Family Law Attorney Ryan Besinque Discusses Divorce, Custody, and Supp …
Families facing divorce, child custody, or child support disputes in New York often experience stress, confusion, and legal uncertainty. Having the support of a Manhattan family law attorney (https://www.besinquelaw.com/family-law-attorney/) is crucial during these moments, particularly in a city as fast-paced and demanding as New York. Ryan Besinque of The Law Office of Ryan Besinque offers legal representation for those navigating family law matters in the New York County Family Court…
Queens Construction Accident Lawyer Keetick L. Sanchez Discusses Dangers of Fall …
Queens, NY - Falling objects are a common and dangerous threat on construction sites, and Queens construction accident lawyers at K L Sanchez Law Office, P.C. (https://accidentlawyer-queens.com/what-kind-of-construction-accident-injuries-are-caused-by-falling-objects/) are working to raise awareness about the serious injuries these accidents can cause. According to Keetick L. Sanchez, these incidents can result in long-term or even fatal consequences for construction workers and site visitors. As one of the more frequent hazards on active…
The Secret of Life - Ancient Biotechnology Evolution
Image: https://timesfeatured.com/wp-content/uploads/2025/12/Zarkaish-Pic-744x1024.jpeg
Dr. Zarkaish Ismail - whose identify means "Gold Feather" - is a biotechnology and dermatology entrepreneur and the Co-Founder-Chief Executive Officer of Kore Secrets Trademark , a revolutionary biotechnology lab and manufacturing firm primarily based in United States, who channels deep scientific biotechnology into concrete social function from a number of historical communities: increasing entry to high quality healthcare via the inclusion of ancient organic information, stem cells, exosomes,…
Jamie Sinclaire Sets Marketing Standards With Data-Powered Creativity
Jamie Sinclaire establishes structured marketing standards using data and creative insights to improve campaign clarity, audience engagement, and measurable performance.
Jamie Sinclaire introduced a structured framework for marketing that combines data insights with creative processes. The approach guides planning, writing, designing, and measuring content to improve clarity, consistency, and audience engagement.
The standards were developed after reviewing marketing campaigns across multiple sectors. Jamie Sinclaire [https://www.issuewire.com/jamie-sinclaire-leads-marketing-impact-through-ethical-practices-1847768167376449] observed that teams often collected large amounts…
More Releases for Atopic
Rising Prevalence Of Atopic Dermatitis Is A Key Catalyst For The Growth Of The A …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Atopic Dermatitis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The scope of the atopic dermatitis market has experienced substantial expansion recently, projected to increase from $8.61 billion in 2024 to reach $9.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.7%;…
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
